| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Cancer discovery 10 (1), 54-71, 2020 | 1154 | 2020 |
| Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors … V Ludovini, F Bianconi, L Pistola, R Chiari, V Minotti, R Colella, D Giuffrida, ... Journal of thoracic oncology 6 (4), 707-715, 2011 | 204 | 2011 |
| The KRAS (G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020; 10: 54–71. doi … J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Nat Can 1 (1), 25-7, 2020 | 202 | 2020 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 103 | 2017 |
| Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ... Cancer research 83 (1), 141-157, 2023 | 88 | 2023 |
| Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell … V Ludovini, I Floriani, L Pistola, V Minotti, M Meacci, R Chiari, ... Journal of thoracic oncology 6 (12), 2018-2026, 2011 | 72 | 2011 |
| Reverse phase protein microarrays E Baldelli, V Calvert, A Hodge, A VanMeter, EF Petricoin, M Pierobon Molecular profiling: methods and protocols, 149-169, 2017 | 58 | 2017 |
| The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells E Parasido, GS Avetian, A Naeem, G Graham, M Pishvaian, E Glasgow, ... Molecular Cancer Research 17 (9), 1815-1827, 2019 | 56 | 2019 |
| Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology F Bianconi, E Baldelli, V Ludovini, L Crinò, A Flacco, P Valigi Biotechnology advances 30 (1), 142-153, 2012 | 54 | 2012 |
| Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations V Ludovini, F Bianconi, L Pistola, V Minotti, R Chiari, R Colella, ... Cancer chemotherapy and pharmacology 69, 1289-1299, 2012 | 47 | 2012 |
| Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN M Codrich, E Dalla, C Mio, G Antoniali, MC Malfatti, S Marzinotto, ... Journal of Experimental & Clinical Cancer Research 40, 1-17, 2021 | 39 | 2021 |
| Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways AR Soltis, NW Bateman, J Liu, T Nguyen, TJ Franks, X Zhang, CL Dalgard, ... Cell Reports Medicine 3 (11), 2022 | 38 | 2022 |
| Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer … E Baldelli, EB Haura, L Crinò, DW Cress, V Ludovini, MB Schabath, ... PROTEOMICS–Clinical Applications 9 (9-10), 928-937, 2015 | 37 | 2015 |
| Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy MI Sereni, E Baldelli, G Gambara, J Deng, L Zanotti, E Bandiera, ... Proteomics 15 (2-3), 365-373, 2015 | 33 | 2015 |
| Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors E Baldelli, G Bellezza, EB Haura, L Crinó, WD Cress, J Deng, V Ludovini, ... Oncotarget 6 (32), 32368, 2015 | 31 | 2015 |
| AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers MM Abu-Khalaf, K Alex Hodge, C Hatzis, E Baldelli, E El Gazzah, ... NPJ Precision Oncology 7 (1), 18, 2023 | 30 | 2023 |
| CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ... Cell reports 37 (9), 2021 | 28 | 2021 |
| A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray E Pin, S Stratton, C Belluco, L Liotta, R Nagle, KA Hodge, J Deng, T Dong, ... Molecular Oncology 10 (10), 1585-1594, 2016 | 28 | 2016 |
| Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients V Ludovini, A Flacco, F Bianconi, M Ragusa, J Vannucci, G Bellezza, ... Cancer chemotherapy and pharmacology 71 (3), 671-680, 2013 | 27 | 2013 |
| Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer JE Klomp, JN Diehl, JA Klomp, AC Edwards, R Yang, AJ Morales, ... Science 384 (6700), eadk0850, 2024 | 24 | 2024 |
